H
HeyPsych
PsychTrails™TreatmentsConditionsResourcesFor CliniciansAbout

Stay updated on mental health treatments

Get the latest research, treatment updates, and evidence-based insights delivered to your inbox. No spam, just valuable mental health information.

Coming Soon

Newsletter subscription will be available soon.

H
HeyPsych

Evidence-based mental health treatment education platform. Helping you make informed decisions about your mental health journey.

Treatments

  • Medications
  • Interventional
  • Investigational
  • Alternative
  • Therapy
  • Supplements

Conditions

  • Depression
  • Anxiety
  • ADHD
  • Bipolar
  • All Conditions

Resources

  • Assessments & Screeners
  • Support & Community
  • Digital Tools
  • Knowledge Hub
  • PsychTrails™

Company

  • About Us
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 HeyPsych (PsychTrails™). All rights reserved.

Made with for better mental health
v2.2.0

Brexanolone (Zulresso)

FDA Approved 2019

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published December 1, 2025•Updated December 1, 2025•Reviewed December 1, 2025

Clinical summary for Brexanolone (Zulresso): Brexanolone (Zulresso) is a one-time IV treatment for postpartum depression. You receive it as a continuous drip over about 2½ days in a hospital or certified center. Many patients start to feel noticeably better in just a few days, and improvements can last for weeks. Because it can cause very deep sleep or even brief loss of consciousness, you’re monitored closely with continuous oxygen and sedation checks, and a caregiver must be present to help with your baby. You cannot drive until the effects fully wear off. It’s a powerful option for severe PPD when fast relief is needed, but it requires a hospital stay and careful safety monitoring.

What It’s Used For

Brexanolone is specifically approved for postpartum depression (PPD) and is not used as a general antidepressant for other conditions.

Primary Indications

Postpartum Depression (PPD) in patients ≥15 years of age with moderate to severe symptoms.Rapid treatment in cases where symptom severity poses high risk to the birthing parent or infant (e.g., inability to care for self or baby, failure of or limited response to oral treatments, or urgent need for faster improvement).Patients able to stay in a certified facility for the full 60-hour infusion with continuous monitoring and caregiver support for infant care.

Off-Label Uses

Not routinely used off-label outside PPD, as the approval, safety monitoring, and REMS are specific to postpartum depression.

What People Often Feel During Treatment

Experiences vary, but these are common themes reported by patients receiving brexanolone for postpartum depression:

Mood & Anxiety

""By the second day, the heavy fog started to lift.""

How Fast It Works

Brexanolone is designed to work quickly compared with traditional oral antidepressants.

The medication is given as a 60-hour continuous IV infusion with stepwise dose changes.

Some patients notice mood changes during or shortly after completion of the infusion; full effect is usually assessed at the end of the 60-hour treatment.

Improvement in depression symptoms can persist for weeks in many patients after the infusion ends.

Sedation can occur at any point during the infusion and may require dose interruption or reduction.

How Well It Works for Postpartum Depression

Change in depression rating scores at 60 hours

Clinically meaningful reduction vs placebo in trials
vs Brexanolone produced greater symptom reduction and higher remission rates vs placebo at 60 hours.
In pivotal clinical trials, women with moderate to severe postpartum depression who received brexanolone had significantly larger decreases in standardized depression scores by the end of the 60-hour infusion than those receiving placebo. A higher percentage of brexanolone-treated patients met criteria for remission (no longer in the depressive range). Many maintained these benefits at follow-up after the infusion.

Critical Safety Information

Critical Safety Information

Major risk: excessive sedation and sudden loss of consciousness during infusion.
  • →You will be continuously monitored, including oxygen levels and sedation checks, throughout the infusion.
  • →You must have a caregiver available to help care for your baby during the infusion because you may be too sleepy to safely care for your child.
  • →Tell staff immediately if you feel like you cannot stay awake or feel you might pass out.
  • →Do not drive, sign important documents, or do anything requiring full alertness until your care team confirms it is safe after the infusion.
  • →Avoid alcohol and discuss all other medications and supplements with your care team before treatment.
  • →Report any new or worsening depression, anxiety, or thoughts of self-harm right away.

Side Effects

Most common side effects are drowsiness/sedation, dizziness, and dry mouth. A serious but less common risk is sudden loss of consciousness.

Common Things People Notice

  • Feeling very sleepy, drowsy, or sedated.
  • Dizziness or feeling like you might faint.
  • Dry mouth.
  • Flushing or feeling warm.
  • Occasional diarrhea or indigestion.

Common Side Effects

Up to ~21%
Sedation / Drowsiness / Sedated State— You may sleep much more than usual or feel deeply sedated during the infusion. Staff will check on you frequently and may pause or slow the infusion if needed.
Up to ~13% for each
Dizziness, Presyncope, Vertigo— You might feel lightheaded, like the room is spinning, or like you’re about to pass out. Call your nurse immediately if this happens.
3–11%
Dry Mouth— Sipping water or using sugar-free gum/lozenges (if allowed) can help, but ask your care team what is safe during the infusion.
Up to ~5%
Flushing / Hot Flashes— You may feel warm or notice redness in your face or chest; this is usually brief but should still be mentioned to staff.
Low (around 2–3%)
GI Symptoms (Diarrhea, Dyspepsia)— Mild stomach upset or loose stools may occur; tell your team if it becomes bothersome.

⚠️ Serious Side Effects

  • Loss of consciousness (brief or prolonged episodes where you are not responsive).
  • Impaired consciousness or unresponsiveness requiring immediate medical evaluation.
  • Significant hypoxia (low oxygen saturation on pulse oximetry).
  • Serious allergic reactions: rash, swelling, trouble breathing, or anaphylaxis.
  • Emergent suicidal thoughts or behaviors, severe mood swings, or agitation.
  • Falls or injuries related to sudden sedation or loss of consciousness.

Important Drug & Substance Interactions

Brexanolone is a CNS depressant. Anything else that makes you drowsy can increase the risk of excessive sedation, breathing problems, or loss of consciousness.

With: Alcohol

Risk: Additive CNS depression, greatly increased risk of excessive sedation, respiratory depression, and loss of consciousness.

Action: Avoid alcohol before, during, and immediately after the brexanolone infusion.

With: Opioids (e.g., morphine, oxycodone, hydrocodone, fentanyl)

Risk: Increased risk of severe sedation, respiratory depression, and overdose.

Action: Use only if absolutely necessary, at the lowest effective dose, with close monitoring. Coordinate pain management with the brexanolone team.

With: Benzodiazepines and Other Sedatives (e.g., lorazepam, zolpidem, eszopiclone, barbiturates)

Risk: Major additive sedative effects, higher risk of loss of consciousness and breathing problems.

Action: Avoid or minimize doses; if required, monitor extremely closely in a controlled setting.

With: Sedating Antidepressants, Antipsychotics, Antihistamines, and Sleep Medications

Risk: Extra drowsiness, dizziness, and impaired coordination.

Action: Review all medications before infusion; reduce or hold other sedatives when possible during treatment.

With: MAOIs and Certain Other Antidepressants

Risk: Increased CNS depression; complex interactions requiring specialist judgment.

Action: Psychiatric and perinatal mental health specialists should coordinate therapy and monitoring.

With: Strong CNS Depressants or Substances of Misuse (e.g., kratom, kava, GHB/oxybate)

Risk: Potentially dangerous, unpredictable sedation and respiratory depression.

Action: Avoid. Disclose all substances, including herbal and recreational, to your treatment team.

Stopping or Interrupting Treatment

Brexanolone is given as a single 60-hour infusion rather than a long-term daily medication.

Key Points

  • If excessive sedation or loss of consciousness occurs, the infusion is stopped immediately.
  • After recovery, the infusion may be resumed at the same or a reduced rate if clinically appropriate.
  • If hypoxia (low oxygen levels) occurs, the infusion is stopped and not resumed.
  • There is no traditional long-term taper because treatment is time-limited and given only in the monitored setting.
  • Any ongoing antidepressant or psychotherapy regimen should be continued or adjusted separately after the infusion.

Dosing Information

Adult Dosing

ppd initial: Start infusion early in the day to allow recognition of sedation.

ppd schedule: [object Object]

toxicity adjustment: [object Object]

renal: No adjustment needed for eGFR ≥15 mL/min/1.73 m²; use not recommended if eGFR <15 mL/min/1.73 m².

hepatic: No dose adjustment required for hepatic impairment.

simple explanation: The dose starts low, gradually increases, then tapers down again over a total of 60 hours. Rates can be lowered or stopped if you become too sleepy or have other side effects.

Pregnancy, Breastfeeding, and Special Groups

Brexanolone is specifically aimed at postpartum patients; considerations around pregnancy and lactation are critical.

👶Pregnancy

Based on mechanism and animal data, in utero exposure may cause fetal harm. Brexanolone is generally initiated after delivery, not during pregnancy. If depression requires treatment during pregnancy, other options with more established safety profiles are preferred.

🤱Breastfeeding

Brexanolone (identical to endogenous allopregnanolone) appears in breast milk at low levels, and relative infant dose estimates are <10%. Low oral bioavailability further limits infant exposure. However, because the birthing parent may be deeply sedated or lose consciousness, close supervision is essential for any breastfeeding or pumping during the infusion. Decisions about breastfeeding should balance maternal benefit, infant exposure, and safety/logistical issues.

👧Children & Adolescents (Under 18)

Approved for patients ≥15 years of age for postpartum depression. Not indicated in younger adolescents or children.

👴Older Adults (65+)

PPD population is typically younger; data in older adults are limited. Theoretically, older patients would be at higher risk of sedation, falls, and other CNS effects.

🔬Liver Impairment

No dose adjustment needed, but global medical fragility and polypharmacy should be considered.

💧Kidney Impairment

Avoid use if eGFR <15 mL/min/1.73 m² due to accumulation of the solubilizing agent. Monitor kidney function in at-risk patients.

Clinical Monitoring

  • Continuous pulse oximetry (oxygen saturation) with alarms throughout the 60-hour infusion.
  • Sedation level checks at least every 2 hours during normal wake times, using a standardized sedation scale.
  • Vital signs monitoring (blood pressure, heart rate, respiratory rate).
  • Mental status: alertness, orientation, presence of confusion or loss of consciousness.
  • Depression severity and suicidality: before, during, and after infusion.
  • Renal function in patients with risk factors or known kidney disease.
  • Fall risk and safety, particularly when mobilizing or going to the bathroom.
  • Infant safety: ensure a responsible adult is present to care for the baby at all times while the patient is sedated.

Available Formulations

  • Intravenous solution (preservative-free): 100 mg/20 mL vials for dilution and continuous infusion.
  • No oral or home-use formulations are available.
  • Administered via programmable peristaltic pump through a dedicated IV line (no in-line filter).

How It Works

Brexanolone is a synthetic formulation of allopregnanolone, an endogenous neurosteroid that enhances GABA-A receptor activity. During pregnancy and after delivery, levels of allopregnanolone change dramatically. These shifts may contribute to vulnerability to postpartum depression in some individuals. By positively modulating GABA-A receptors, brexanolone is thought to help restore more normal inhibitory signaling in the brain, which can rapidly relieve depressive and anxiety symptoms in PPD. The exact mechanisms are still being studied.

Place in Treatment Algorithm

Brexanolone occupies a specialized niche in postpartum depression care. It is reserved for moderate to severe PPD when rapid symptom relief is needed and when patients can access a REMS-certified facility and commit to a 60-hour monitored infusion. Many patients will still receive or continue oral antidepressants and psychotherapy alongside or after brexanolone. Because of cost, logistics, and monitoring demands, it is not a first-line option for all PPD cases, but can be life-changing for selected patients with severe, treatment-resistant, or high-risk postpartum depression.

Frequently Asked Questions

What is brexanolone (Zulresso) used for?

Brexanolone is used to treat moderate to severe postpartum depression in patients 15 years and older. It is given as a one-time, 60-hour IV infusion in a certified facility with continuous monitoring.

How is brexanolone given?

It’s given as a continuous intravenous (IV) infusion over 60 hours. The dose starts low, increases to a higher rate, and then tapers back down. You stay in the hospital or a certified center the entire time and are monitored closely for sedation and breathing.

How quickly does brexanolone work?

Many patients notice meaningful improvement in mood by the end of the 60-hour infusion, sometimes even earlier. Unlike traditional antidepressants that can take weeks, brexanolone is designed to produce a relatively rapid effect in postpartum depression.

Why does brexanolone require a REMS program?

Because it can cause excessive sedation and sudden loss of consciousness, brexanolone is only available through the ZULRESSO REMS. This ensures that the infusion happens in a certified facility with continuous monitoring, and that a caregiver is present to help with infant care.

Can I care for my baby during the infusion?

You can interact with your baby, but you must be supervised by another adult at all times because you may become very drowsy or briefly lose consciousness. A caregiver must be present to provide hands-on care and ensure your baby’s safety.

Can I breastfeed while receiving brexanolone?

Small amounts of brexanolone pass into breast milk, but it has low oral bioavailability, so infant exposure is expected to be low. The bigger concern is that you may be too sedated to safely handle your baby. If breastfeeding continues during treatment, close supervision and support are essential. Some patients choose to pump and discard milk during the infusion and resume breastfeeding afterward.

What are the most common side effects?

The most common are drowsiness or sedation, dizziness, feeling like you might faint, dry mouth, flushing, and mild GI upset. A serious but less common side effect is sudden loss of consciousness, which is why continuous monitoring is required.

Can I drive after brexanolone treatment?

You should not drive or operate machinery until the sedative effects have fully resolved and your care team confirms that it is safe. This may extend beyond the end of the infusion depending on how you feel.

What happens if I become too sleepy during the infusion?

If you show signs of excessive sedation or loss of consciousness, the infusion is stopped right away. Once you recover, your team may restart it at the same or a lower rate, or decide not to continue depending on your safety and response.

Will I still need other treatments after brexanolone?

Often yes. Many patients continue or start oral antidepressants and psychotherapy as ongoing treatment. Brexanolone can provide rapid improvement, but long-term care plans usually include medication, therapy, and support to maintain recovery.

This medication information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Never take medication without a prescription from a licensed healthcare provider.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists